Development of receptor targeting DDS of oral cancer using the nanosize particle

点击翻译按钮获取中文摘要

In present study, we developed the bispecific antibody that can recognize both nanosize particle (Minicell) and EGF receptor (EGFR). At first, expression level of Minicell on the cultured oral cancer cell line was examined by using this antibody and we confirmed that its expression was increased in proportion to that of EGFR. Next, we measured the antitumor efficacy by direct injection of anticancer drug packaged Minicell into tumour xenografts of nude mice. As a result, high EGFR expression tumor group showed more effective antitumor efficacy than low EGFR expression group. But unfortunately, the result didn’t reveal the statistical significance.